Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies.
作者信息
Schmidt Ann Marie, Sorci-Thomas Mary G, Chen Yabing, Hegele Robert A
机构信息
Diabetes Research Program, Department of Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York (A.M.S.).
Department of Medicine, Division of Endocrinology and Molecular Medicine (M.G.S.-T.), Medical College of Wisconsin, Milwaukee.
出版信息
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1093-1095. doi: 10.1161/ATVBAHA.123.319633. Epub 2023 Jun 1.
Abstract
摘要
相似文献
1
Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies.学术-产业合作关系：透明度、潜在利益冲突与前沿技术交流
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1093-1095. doi: 10.1161/ATVBAHA.123.319633. Epub 2023 Jun 1.
2
Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry?自我监管和利益冲突声明仍是医生与行业关系的基准吗？
Med J Aust. 2008 Sep 1;189(5):263-6. doi: 10.5694/j.1326-5377.2008.tb02020.x.
3
The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials.报告的 III 期癌症试验编辑作者利益冲突的普遍性及其影响。
Contemp Clin Trials. 2012 Sep;33(5):1019-22. doi: 10.1016/j.cct.2012.05.011. Epub 2012 Jun 1.
4
[Transparency, reliability and conflict of interest].[透明度、可靠性与利益冲突]
Ugeskr Laeger. 2011 Aug 15;173(33):1989.
5
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.欧洲心脏病学会各国家心血管杂志的利益冲突政策及披露要求
Rev Esp Cardiol (Engl Ed). 2012 May;65(5):471-8. doi: 10.1016/j.recesp.2012.02.002. Epub 2012 Mar 30.
6
Conflict of interest policies should be better reported in dental journals.牙科期刊应更好地报道利益冲突政策。
J Can Dent Assoc. 2012;78:c52.
7
Conflicts of interest in medical publishing: it's all about trustworthiness.医学出版中的利益冲突：关键在于可信度。
Br J Dermatol. 2015 Nov;173(5):1255-7. doi: 10.1111/bjd.14157.
8
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.欧洲心脏病学会各国家心血管杂志的利益冲突政策及披露要求
Rev Port Cardiol. 2012 Apr;31(4):329-36. doi: 10.1016/j.repc.2011.12.014.
9
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.欧洲心脏病学会国家心血管期刊的利益冲突政策和披露要求。
Eur Heart J. 2012 Mar;33(5):587-94. doi: 10.1093/eurheartj/ehr464.
10
[Conflicts of interest: transparency, not witch-hunts].[利益冲突：透明度，而非政治迫害]
Presse Med. 2005 Sep 10;34(15):1052-4. doi: 10.1016/s0755-4982(05)84114-4.
引用本文的文献
1
Perspectives on the role of industry in informatics research and authorship.行业在信息学研究和著述中的作用的观点。
J Am Med Inform Assoc. 2024 Apr 19;31(5):1206-1210. doi: 10.1093/jamia/ocae063.
2
The landscape of biomedical research funding in Brazil: a current overview.巴西生物医学研究经费的全貌：当前概述。
Int Braz J Urol. 2024 Mar-Apr;50(2):209-222. doi: 10.1590/S1677-5538.IBJU.2024.9905.
本文引用的文献
1
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing.靶向 PCSK9 的新方法：小干扰核糖核酸和基因组编辑。
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1081-1092. doi: 10.1161/ATVBAHA.122.317963. Epub 2023 Jun 1.
2
Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to Protein.填补创新罕见病治疗模式中的临床药理学空白：从 DNA 到 RNA 再到蛋白质。
J Clin Pharmacol. 2022 Dec;62 Suppl 2:S95-S109. doi: 10.1002/jcph.2172.
3
An Overview of Genome Editing in Cardiovascular and Metabolic Diseases.基因组编辑在心血管和代谢疾病中的概述。
Adv Exp Med Biol. 2023;1396:3-16. doi: 10.1007/978-981-19-5642-3_1.
4
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting in Nonhuman Primate and Mouse Models.在非人类灵长类动物和小鼠模型中靶向 的一种新型单疗程 CRISPR 碱基编辑疗法的疗效和安全性。
Circulation. 2023 Jan 17;147(3):242-253. doi: 10.1161/CIRCULATIONAHA.122.062132. Epub 2022 Oct 31.
5
The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms.《拜杜法案》40周年：成就、挑战与可能的改革。
J Health Polit Policy Law. 2022 Dec 1;47(6):879-895. doi: 10.1215/03616878-10041247.
6
Therapeutic application of genome editing in dyslipidemia.基因组编辑在血脂异常中的治疗应用。
Curr Opin Lipidol. 2022 Apr 1;33(2):133-138. doi: 10.1097/MOL.0000000000000805.
7
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.体内编辑灵长类动物 PCSK9 的腺嘌呤碱基可降低 LDL 胆固醇水平。
Nat Biotechnol. 2021 Aug;39(8):949-957. doi: 10.1038/s41587-021-00933-4. Epub 2021 May 19.
8
Insulin's centenary: the birth of an idea.胰岛素百年：理念诞生。
Lancet Diabetes Endocrinol. 2020 Dec;8(12):971-977. doi: 10.1016/S2213-8587(20)30337-5. Epub 2020 Oct 29.
9
Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.小干扰 RNA 对前蛋白转化酶枯草溶菌素/克酶 9：改变 LDL 胆固醇降低策略。
Curr Opin Lipidol. 2020 Aug;31(4):182-186. doi: 10.1097/MOL.0000000000000691.
10
Nonregulated Interventions, Clinical Trial Registration, and Editorial Responsibility.非规范干预措施、临床试验注册与编辑责任
Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005721. doi: 10.1161/CIRCOUTCOMES.119.005721. Epub 2019 Jun 11.
Zotero 插件